
https://www.science.org/content/blog-post/tamiflu-good-anything-not
# Tamiflu: Good For Anything, Or Not? (January 2006)

## 1. SUMMARY
This 2006 article addresses the confusion surrounding neuraminidase inhibitors (Tamiflu and Relenza) versus older adamantane-class flu antivirals. The piece notes that the CDC had recently warned that prevalent H3N2 seasonal flu strains carried mutations making the older adamantanes ineffective, while a Lancet meta-analysis concluded there was no solid evidence that Tamiflu or Relenza worked against either standard seasonal flu or avian H5N1 bird flu. The author distinguishes between proven ineffectiveness of older drugs and pure absence of human clinical evidence for Tamiflu/Relenza against bird flu, pointing out that no published human studies existed at the time—only cell culture data.

## 2. HISTORY
The period following this article revealed several concrete outcomes. Public health agencies stockpiled oseltamivir (Tamiflu) broadly during the 2009 H1N1 pandemic and later COVID-19, but real-world effectiveness proved more modest than anticipated. Meta-analyses by the Cochrane Collaboration and others indicated Tamiflu shortened flu symptom duration modestly but did not clearly reduce hospitalizations or complications. Both the adamantanes and some neuraminidase inhibitors faced rising resistance; by the late 2000s, widespread resistance to adamantanes rendered them largely obsolete, and seasonal H1N1 developed oseltamivir resistance around 2008–2009. Regulatory approvals reflected this complexity: Tamiflu received pediatric indications but safety concerns emerged regarding neuropsychiatric events. Massive government stockpiling occurred despite moderate evidence, creating a durable market, while zanamivir (Relenza) saw limited adoption due to inhalation route constraints.

## 3. PREDICTIONS
- **Adamantane retirement**: The article noted experts recommended retiring adamantanes; this largely came true as widespread resistance made them clinically obsolete and they were dropped from guidelines.
- **Tamiflu/Relenza effectiveness against standard flu**: The Lancet meta-analysis and the author were skeptical; subsequent evidence showed modest symptom reduction but unclear benefit on serious outcomes, matching the skepticism.
- **Bird flu effectiveness unknown**: The article stressed absence of human data; H5N1 never caused sustained human-to-human spread, so controlled efficacy trials remained impossible. Limited case reports and observational data from H5N1 and other avian strains did not establish clear efficacy, validating that headline claims of ineffectiveness were premature.
- **Market uptake**: Despite clinical ambiguity, Tamiflu sales surged with pandemic preparedness stockpiling; the market behaved more on perceived than proven benefit.

## 4. INTEREST
Rating: **7/10**
This article identified core evidence gaps (no human data for H5N1) and distinguished true ineffectiveness from absence of data—a critical distinction that shaped subsequent policy debates and demonstrated how pandemic preparedness investment proceeded despite thin evidence, ultimately revealing tensions between public health urgency and evidence-based medicine.


----
_model_params = {'model': 'nex-agi/deepseek-v3.1-nex-n1:free', 'input': '20060119-tamiflu-good-anything-not.txt', 'reasoning': {'effort': 'high'}, 'text': {'verbosity': 'medium'}, 'prompt-template': 'prompt-template-2'}_